药物耐药不安腿综合征:现实世界的经验
Peyman Petramfar1, Joseph Jankovic1
1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
不安腿综合征 (RLS) 很难长期管理. 较年轻的发病年龄,家族病史和最初使用多巴胺激动剂预测了耐火性RLS,建议对这种治疗保持谨慎.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 遗传学 遗传学 是一个
背景情况:
- 不安腿综合征 (RLS) 影响5-13%的人口,带来长期管理挑战.
- 在预测RLS对一线疗法的治疗耐药性方面存在重大知识差距.
研究的目的:
- 确定预测耐药不安腿综合征的人口和临床因素.
- 为了区分耐火性和非耐火性RLS患者队列之间的特征.
主要方法:
- 从2018年1月到2023年9月在运动障碍诊所进行的回顾性研究.
- 药物耐药性RLS患者的临床和人口统计数据与"良性"队列进行比较.
- 利用了132名RLS患者的数据,其中23人被归类为药物耐药.
主要成果:
- 耐火性RLS病例在发病时显著年轻 (39.3岁与53.5岁) 和疾病持续时间较长 (26.7岁与14.0岁).
- 在一级亲属中,RLS的阳性家族史在耐火组中更为普遍 (56.5%与15.5%对比).
- 多巴胺激动剂在耐火性RLS队列中更频繁地作为主要药物开始使用 (p=0.006).
结论:
- 发病时年龄较小,疾病持续时间较长,最初使用多巴胺激动剂,以及家族史预测耐火性RLS.
- 建议谨慎使用多巴胺激动剂,特别是在年轻的RLS患者中.
- 毒素可能是一个可行的二线治疗药物耐药性RSL.
更多相关视频
11:29Real-time Video Projection in an MRI for Characterization of Neural Correlates Associated with Mirror Therapy for Phantom Limb Pain
Published on: April 20, 2019
10:08The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
Published on: August 25, 2022
相关概念视频
Restless Leg Syndrome and Night Terrors
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
REM Sleep Behavior Disorder
RBD is significantly associated with...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Management of Insomnia
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
